NCT06828458 Determining Elements of Anti-Fungal Immunity in BURN Patients
| NCT ID | NCT06828458 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Condition | Burn |
| Study Type | OBSERVATIONAL |
| Enrollment | 327 participants |
| Start Date | 2025-04-23 |
| Primary Completion | 2030-10-23 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 327 participants in total. It began in 2025-04-23 with a primary completion date of 2030-10-23.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Scientific justification Invasive fungal diseases (IFDs) pose a substantial threat, especially in immunocompromised patients, necessitating urgent research focus and therapeutic advancements. The IFI-BURN study, involving a cohort of patients with severe burn injury (n=276), revealed a significant IFD incidence of 31.6% and underscored their critical impact on morbidity and mortality. While fungi are present everywhere, for moulds within the environment and for yeasts within our microbiota, why certain patients develop IFDs and others do not, remains poorly understood. The answer most likely resides in the impact of the burn injury on the immune response, loss of skin barrier and particular predisposing immune phenotype of patients. The immune system is composed of both cellular and humoral components, but the latter is far less studied in antifungal immunity although they exert multiple antimicrobial mechanisms.
Eligibility Criteria
Inclusion Criteria: Burn patients * Adult patients ≥ 18 years old * Admission \< 4 days following burn injury * Total burn surface Area ≥ 15% * Non opposition of the patient or his/her relatives to the research * Affiliation to social security or any health insurance Exclusion Criteria: * Pregnancy * Opposition of the patient or his/her relatives * Decision not to resuscitate or to limit or stop active therapies
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06828458 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Burn. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06828458 currently recruiting?
Yes, NCT06828458 is actively recruiting participants. Contact the research team at emmanuel.dudoignon@aphp.fr for enrollment information.
Where is the NCT06828458 trial being conducted?
This trial is being conducted at Paris, France.
Who is sponsoring the NCT06828458 clinical trial?
NCT06828458 is sponsored by Assistance Publique - Hôpitaux de Paris. The trial plans to enroll 327 participants.